Literature DB >> 21109184

Challenging and emerging pathogens in cystic fibrosis.

A M M de Vrankrijker1, T F W Wolfs, C K van der Ent.   

Abstract

Cystic fibrosis (CF) lung disease is characterised by chronic inflammation and infection. Patients are predominantly infected by specific pathogens, of which Staphylococcus aureus and Pseudomonas aeruginosa are the most important. In recent years however there has been an increasing number of reports on potentially emerging and challenging pathogens like Stenotrophomonas maltophilia, Non-tuberculous mycobacteria, highly prevalent P. aeruginosa clones, methicillin resistant Staphylococcus aureus and Burkholderia cepacia. Also, a role for viral infections in the pathogenesis of CF lung disease has increasingly been recognised. It is not always clear whether or how these pathogens influence the progression of CF lung disease and how they should be treated. In this review, the epidemiology and clinical impact of these pathogens is discussed. Furthermore, treatment strategies of these pathogens in a CF setting are reviewed.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21109184     DOI: 10.1016/j.prrv.2010.07.003

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  16 in total

1.  The lung tissue microbiome in chronic obstructive pulmonary disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Shizu Hayashi; W Mark Elliott; John E McDonough; John V Gosselink; Joel Cooper; Don D Sin; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

Review 2.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

3.  Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.

Authors:  Keith Poole; Christie Gilmour; Maya A Farha; Erin Mullen; Calvin Ho-Fung Lau; Eric D Brown
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

4.  Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis.

Authors:  Amy E Peterson; Amit S Chitnis; Nan Xiang; Joseph M Scaletta; Robert Geist; Jennifer Schwartz; Jamie Dement; Elizabeth Lawlor; John J Lipuma; Heather O'Connell; Judith Noble-Wang; Alexander J Kallen; D Charles Hunt
Journal:  Am J Infect Control       Date:  2013-08-21       Impact factor: 2.918

5.  Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.

Authors:  Arianna Pompilio; Valentina Crocetta; Marco Scocchi; Stefano Pomponio; Valentina Di Vincenzo; Mario Mardirossian; Giovanni Gherardi; Ersilia Fiscarelli; Giordano Dicuonzo; Renato Gennaro; Giovanni Di Bonaventura
Journal:  BMC Microbiol       Date:  2012-07-23       Impact factor: 3.605

6.  Insights into the evolution of sorbitol metabolism: phylogenetic analysis of SDR196C family.

Authors:  Agustín Sola-Carvajal; María Inmaculada García-García; Francisco García-Carmona; Álvaro Sánchez-Ferrer
Journal:  BMC Evol Biol       Date:  2012-08-16       Impact factor: 3.260

7.  Microbial communities in the upper respiratory tract of patients with asthma and chronic obstructive pulmonary disease.

Authors:  HeeKuk Park; Jong Wook Shin; Sang-Gue Park; Wonyong Kim
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

8.  AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa.

Authors:  Calvin Ho-Fung Lau; Thomas Krahn; Christie Gilmour; Erin Mullen; Keith Poole
Journal:  Microbiologyopen       Date:  2014-12-01       Impact factor: 3.139

9.  Identification of Pseudomonas aeruginosa phenazines that kill Caenorhabditis elegans.

Authors:  Brent Cezairliyan; Nawaporn Vinayavekhin; Daniel Grenfell-Lee; Grace J Yuen; Alan Saghatelian; Frederick M Ausubel
Journal:  PLoS Pathog       Date:  2013-01-03       Impact factor: 6.823

10.  Effects of green tea compound epigallocatechin-3-gallate against Stenotrophomonas maltophilia infection and biofilm.

Authors:  Pedrina G Vidigal; Mathias Müsken; Katrin A Becker; Susanne Häussler; Jost Wingender; Eike Steinmann; Jan Kehrmann; Erich Gulbins; Jan Buer; Peter Michael Rath; Jörg Steinmann
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.